COMPOSITION OF TANNIC ACID AND VITAMIN D AND METHODS OF USE
Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.
1 . A composition comprising:
a) a first agent that blocks elastin production; and
b) a second agent that promotes elastin production,
wherein the second agent is present at a concentration of 0.1 nM to 100 nM.
2 . The composition of claim 1 , wherein the second agent neutralizes blocking of elastin production by the first agent.
3 . The composition of claim 1 , wherein the first agent is a moisturizing agent.
4 . The composition of claim 3 , wherein the moisturizing agent is hyaluronic acid.
5 . The composition of claim 4 , wherein the hyaluronic acid is present in the composition at a concentration of about 10 μg/mL to about 100 μg/mL.
6 . The composition of claim 3 , wherein the moisturizing agent is ferulic acid.
7 . The composition of claim 6 , wherein the ferulic acid is present in the composition at a concentration of about 1 μg/mL to about 15 μg/mL.
8 . The composition of claim 3 , wherein the moisturizing agent is vitamin D.
9 . The composition of claim 8 , wherein the vitamin D is vitamin D 3.
10 . The composition of claim 8 , wherein the vitamin D is present in the composition at a concentration of about 0.01 wt % to about 10 wt %.
11 . The composition of claim 1 , wherein the second agent is a polyphenol.
12 . The composition of claim 11 , wherein the polyphenol is tannic acid.
13 . The composition of claim 11 , wherein the polyphenol is ellagic acid.
14 . The composition of claim 1 , wherein the second agent is present in the composition at a concentration of at most 50 nM.
15 - 33 . (canceled)
34 . The composition of claim 1 , further comprising an elastin-derived peptide.
35 - 41 . (canceled)
42 . A method of enhancing elastin formation comprising:
administering to a subject in need thereof a therapeutically-effective amount of a composition, wherein the composition comprises:
i. a first agent that blocks elastin production; and
ii. a second agent that promotes elastin production,
wherein the second agent is present at a concentration of 0.1 nM to 100 nM.
43 - 74 . (canceled)
75 . The method of claim 42 , wherein the composition administered to the subject further comprises an elastin-derived peptide.
76 - 82 . (canceled)
83 . The method of claim 42 , wherein the administering enhances elastin formation in the subject by at least 25% as compared to administration of a control, wherein the control is an analogous composition that lacks the second agent.
84 . The method of claim 42 , wherein the administering enhances collagen formation by at least 25% as compared to the control.
85 - 86 . (canceled)
87 . A method of enhancing elastin formation, the method comprising:
administering to a subject in need thereof a therapeutically-effective amount of a composition, wherein the composition comprises:
i. a first agent that blocks elastin production; and
ii. a second agent that promotes elastin production,
wherein the administering enhances elastin formation by at least 25% as compared to administration of a control, wherein the control is an analogous composition that lacks the second agent.
88 - 89 . (canceled)